Liraglutide for psychiatric disorders: clinical evidence and challenges

Camkurt, Mehmet Akif; Lavagnino, Luca; Zhang, Xiang Y; Teixeira, Antônio Lúcio

doi:10.1515/hmbci-2018-0031

Cited by 16 publications

(17 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This does not invalidate the repurpose of anti-type 2 diabetes drugs to prevent or delay AD progression. Indeed, increasing evidence demonstrates the beneficial effects of, e.g., GLP-1 mimetics (including liraglutide) against AD [18][19][20]. Among them, we emphasize the liraglutide-induced recovery of brain glucose metabolism (whose changes may start before the onset of brain atrophy and neurodegeneration) [77][78][79][80][81][82][83].…”

Section: Discussionmentioning

confidence: 93%

“…The key neuropathological hallmarks of AD are the deposition of Aβ and hyperphosphorylated tau that occur early in disease pathology in brain areas such as the hippocampus and cortex, long before its clinical diagnosis that relies mostly on memory loss and, to a lower extent, in a few biomarkers [18,38]. However, the precise crosslinking mechanisms that occur across this timeframe remain debatable.…”

Section: Effect Of Liraglutide Treatment On Brain and Peripheral Features In Female Micementioning

confidence: 99%

“…AD is closely connected with diabetes (particularly type 2 diabetes; T2D) and obesity-both considered risk factors for AD. Although evidence suggests that AD patients may be more prone to develop co-morbid diabetes or obesity, this remains debatable [18][19][20]. Nevertheless, the features shared by these pathologies (e.g., impaired insulin signaling, and brain glucose transport and metabolism, mitochondrial anomalies, redox imbalance, inflammation and cognitive deficits [20,21]), alongside the failure of most AD clinical trials, led to the hypothesis that antidiabetic drugs may have a therapeutic potential against AD.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

Duarte

Candeias

Alves

et al. 2020

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia worldwide, being characterized by the deposition of senile plaques, neurofibrillary tangles (enriched in the amyloid beta (Aβ) peptide and hyperphosphorylated tau (p-tau), respectively) and memory loss. Aging, type 2 diabetes (T2D) and female sex (especially after menopause) are risk factors for AD, but their crosslinking mechanisms remain unclear. Most clinical trials targeting AD neuropathology failed and it remains incurable. However, evidence suggests that effective anti-T2D drugs, such as the GLP-1 mimetic and neuroprotector liraglutide, can be also efficient against AD. Thus, we aimed to study the benefits of a peripheral liraglutide treatment in AD female mice. We used blood and brain cortical lysates from 10-month-old 3xTg-AD female mice, treated for 28 days with liraglutide (0.2 mg/kg, once/day) to evaluate parameters affected in AD (e.g., Aβ and p-tau, motor and cognitive function, glucose metabolism, inflammation and oxidative/nitrosative stress). Despite the limited signs of cognitive changes in mature female mice, liraglutide only reduced their cortical Aβ1–42 levels. Liraglutide partially attenuated brain estradiol and GLP-1 and activated PKA levels, oxidative/nitrosative stress and inflammation in these AD female mice. Our results support the earlier use of liraglutide as a potential preventive/therapeutic agent against the accumulation of the first neuropathological features of AD in females.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Effect Of Liraglutide Treatment On Brain and Peripheral Features In Female Micementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

Duarte

Candeias

Alves

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Therefore, GLP-1R agonists are currently being intensively studied for their use in the treatment of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease [ 17 , 18 ]. Moreover, there are a few studies which indicate that these compounds may also prove useful in the treatment of neuropsychiatric disorders including depression [ 19 , 20 ].…”

Section: Introductionmentioning

confidence: 99%

Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression

Detka

Głombik

2021

Pharmacol. Rep

View full text Add to dashboard Cite

Depression is a highly prevalent mood disorder and one of the major health concerns in modern society. Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Currently used antidepressant drugs, which mostly target brain monoaminergic neurotransmission, have limited clinical efficacy. Although the etiology of depression has not been fully elucidated, current scientific data emphasize the role of neurotrophic factors deficiencies, disturbed homeostasis between the nervous system and the immune and endocrine systems, as well as disturbances in brain energy metabolism and dysfunctions in the gut-brain axis as important factors in the pathogenesis of this neuropsychiatric disorder. Therefore, therapeutic options that could work in a way other than classic antidepressants are being sought to increase the effectiveness of the treatment. Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system. This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota. Graphic abstract

show abstract

“…Recently, some new researches have demonstrated that Liraglutide has other several effects including controlling weight [5], relieving cardiac disease [6], and preventing psychiatric disorders [7]. Obviously, Liraglutide has a great development prospect.…”

Section: Introductionmentioning

confidence: 99%

Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System

Xie¹,

Zhao²

2018

JBM

View full text Add to dashboard Cite

Objectives: The cost-utility analysis of Liraglutide is aimed at evaluating whether Liraglutide is cost-effective or not after Chinese reformation on medical insurance. The analysis is based on the results of clinical trial conducted in Asia. Methods: We applied a Markov model to estimate the quality-adjusted life years, medical cost and incidence of diabetes-related complications for patients receiving the Liraglutide as an add-on to the metformin treatment. Baseline characteristics were taken from a China's study while the treatment effect is from an Asian study. The related medical cost and utility score were obtained from a local study in China. Having set 30 years' simulations, the incremental cost-effectiveness ratio was calculated comparing with glimepiride treatment. The ratio would be compared with the willingness to pay for a quality-adjusted-life-year (QALY) which is three times of the GDP per capita in Beijing. Sensitivity analysis was also performed. Result: During a period of 30 years, the base-case analysis which takes discount rate at 3% shows that Liraglutide 1.8 mg results in an average incremental cost of CNY 82,671.49, an improvement in 0.12 QALYs and a reduction of incidence of diabetes-related complications comparing to glimepiride. The associated incremental cost-effectiveness ratio is CNY 688,929.08. Conclusion: Long-term project shows that taking Liraglutide as an add-on to the metformin treatment will lead to increasing quality-adjusted life years and reduction of incidence of diabetes-related complications. When the price of Liraglutide is reduced by 43 percent in China's yuan, Liraglutide will be cost-effective in China from the healthcare system perspective taking three times of GDP per capita as our WTP threshold.

show abstract

Liraglutide for psychiatric disorders: clinical evidence and challenges

Cited by 16 publications

References 44 publications

Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression

Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System

Contact Info

Product

Resources

About